MGY825

DRUG2 trials

Sponsors

Moizuzmi Sanae, Novartis Pharmaceuticals

Conditions

Non-small Cell Lung Canceradvanced non-small cell lung cancer

Phase 1

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

TerminatedNCT05275868

Novartis PharmaceuticalsNon-small Cell Lung Cancer

Start: 2022-10-05End: 2025-10-13Updated: 2026-09-04

Phase I study of MGY825 in patients with advanced non-small cell lung cancer

Active, not recruitingJPRN-jRCT2031220278

Moizuzmi Sanaeadvanced non-small cell lung cancer

Start: 2022-10-05Target: 12Updated: 2026-06-29